Phase III trial of low-dose lurasidone (20 mg/day) in patients with schizophrenia.
Latest Information Update: 22 Feb 2012
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Sumitomo Pharma
- 22 Feb 2012 New trial record